Results 51 to 60 of about 1,655 (156)

1H Nuclear Magnetic Resonance: A Future Approach to the Metabolic Profiling of Psychedelics in Human Biofluids?

Frontiers in Psychiatry, 2021
While psychedelics may have therapeutic potential for treating mental health disorders such as depression, further research is needed to better understand their biological effects and mechanisms of action when considering the development of future novel ...
Sylvana Vilca-Melendez, Malin V. Uthaug, Malin V. Uthaug, Julian L. Griffin   +3 more
doaj   +1 more source

Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders

Molecules, 2022
The word “psychedelic” (psyche (i.e., the mind or soul) and delos (i.e., to show)) has Greek origin and was first coined by psychiatrist Humphry Osmond in 1956, who had been conducting research on lysergic acid diethylamide (LSD) at the time. Psychedelic
Henry Lowe, Ngeh Toyang, Blair Steele, Justin Grant, Amza Ali, Lorenzo Gordon, Wilfred Ngwa   +6 more
doaj   +1 more source

Cross-Sectional Associations Between Lifetime Use of Psychedelic Drugs and Psychometric Measures During the COVID-19 Confinement: A Transcultural Study

Frontiers in Psychiatry, 2021
Background: One of the main public health strategies adopted at the beginning of the COVID-19 pandemic consisted of implementing strict lockdowns to stop the transmission of the virus.
Dóra Révész, Genís Ona, Genís Ona, Giordano N. Rossi, Juliana M. Rocha, Rafael G. dos Santos, Rafael G. dos Santos, Rafael G. dos Santos, Jaime E. C. Hallak, Jaime E. C. Hallak, Miguel Á. Alcázar-Córcoles, José C. Bouso, José C. Bouso, José C. Bouso   +13 more
doaj   +1 more source

The psychedelic afterglow phenomenon: a systematic review of subacute effects of classic serotonergic psychedelics

Therapeutic Advances in Psychopharmacology, 2023
Background: Classic serotonergic psychedelics have anecdotally been reported to show a characteristic pattern of subacute effects that persist after the acute effects of the substance have subsided.
Ricarda Evens, Marianna Elisa Schmidt, Tomislav Majić, Timo Torsten Schmidt   +3 more
doaj   +1 more source

Novel psychoactive substances of interest for psychiatry [PDF]

, 2015
Novel psychoactive substances include synthetic cannabinoids, cathinone derivatives, psychedelic phenethylamines, novel stimulants, synthetic opioids, tryptamine derivatives, phencyclidine-like dissociatives, piperazines, GABA-A/B receptor agonists, a ...
Corkery, John, Orsolini, Laura, Papanti, Duccio, Schifano, Fabrizio   +3 more
core   +1 more source

The serotonergic hallucinogen 5-MeO-DMT disrupts cortical activity in rodents

European Neuropsychopharmacology, 2016
Trabajo presentado en el 29th ECNP Congress, celebrado en Viena, Austria, del 17 al 20 de septiembre de ...
Artigas, F.; Riga, M.; Celada, P.
openaire   +3 more sources

Registered Clinical Trials of Ayahuasca and DMT: A Scoping Review

Clinical Pharmacology &Therapeutics, EarlyView.
Interest in ayahuasca and its main component, N,N‐Dimethyltryptamine (DMT), has currently moved from historical and experimental use into modern clinical development. Yet, current evidence is fragmented, and systematic mapping of trial methods and design choices remains limited.
Tijana Stojanović, Kent W. Nilsson, Robert Fredriksson, Helgi B. Schiöth, Thiago C. Moulin   +4 more
wiley   +1 more source

New psychoactive substances (NPS) on cryptomarket fora: An exploratory study of characteristics of forum activity between NPS buyers and vendors [PDF]

, 2017
Background The continual diversification of new psychoactive substances (NPS) circumventing legislation creates a public health and law enforcement challenge, and one particularly challenged by availability on Hidden Web cryptomarkets.
Aldridge, Bancroft, Barratt, Barratt, Barratt, Barratt, Barratt, Broséus, Burns, Caudevilla, Caudevilla, Christin, Cox, Dolliver, Dolliver, Décary-Hétu, Eurobarometer 401, European Commission, European Monitoring Centre for Drugs and Drug Addiction, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), European Union, Evelyn Hearne, Evrard, Global Drug Survey, Hardy, Hearne, Jeffries, Karlsson, Kjellgren, Lavorgna, Lavorgna, Marie Claire Van Hout, Martin, Martin, Martin, Martinotti, Munksgaard, Móró, Ormsby, Orsolini, Phelps, Rhumorbarbe, Rosino, Sande, Schifano, Soska, Soussan, Soussan, Soussan, Tzanetakis, UNODC, van Amsterdam, Van Buskirk, Van Buskirk, Van Hout, Van Hout, Van Hout, Van Hout, Van Hout, Werse, Zawilska   +60 more
core   +1 more source

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source

Interaction of psychedelic tryptamine derivatives with a lipid bilayer [PDF]

, 2023
Naturally occurring psychedelics have been used for a long time as remedies or in religious ceremonies and recreational activities. Recent studies have proven the therapeutic potential of some psychedelic compounds to safely treat a wide range of ...
Hakami Zanjani, Ali Asghar, Khandelia, Himanshu, Zohairi, Fateme   +2 more
core   +1 more source